Physician profile
Diego Ruiz Dasilva
NPI 1912499047
$1,080,380.71
in general payments reported to CMS, 2019-2025
32 companies · $655K in 2025
The $655K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,027 · 2023: $46K · 2024: $379K · 2025: $655K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $674K · Consulting Fee: $242K · Travel and Lodging: $88K · Food and Beverage: $37K · Honoraria: $37K · Education: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $674,490.22 |
| Consulting Fee | $242,405.25 |
| Travel and Lodging | $87,868.60 |
| Food and Beverage | $37,145.57 |
| Honoraria | $36,608.11 |
| Education | $836.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $197,754.14 | 2022-2025 | Skyrizi, Rinvoq, Humira |
| Genzyme Corporation | $190,168.35 | 2022-2025 | |
| Galderma Laboratories, L.P. | $162,134.10 | 2023-2025 | Nemluvio, Aklief |
| Pfizer INC. | $128,731.90 | 2022-2025 | |
| Leo Pharma INC. | $101,081.20 | 2022-2025 | Adbry, Anzupgo, Spevigo |
| Arcutis Biotherapeutics, INC. | $89,790.83 | 2023-2025 | Zoryve |
| Ucb, INC. | $84,813.30 | 2022-2025 | Bimzelx, Cimzia |
| Organon LLC | $39,786.29 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $24,734.57 | 2023-2025 | Ycanth |
| Lilly USA, LLC | $18,343.56 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Janssen Biotech, INC. | $11,625.79 | 2022-2025 | Tremfya |
| Incyte Corporation | $9,994.60 | 2022-2025 | Opzelura, Opzelura |
| Dermavant Sciences, INC. | $7,580.45 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $4,513.34 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $3,699.98 | 2025 | Zoryve |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,840.21 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $1,761.58 | 2022-2025 | Sotyktu |
| Amgen INC. | $708.44 | 2022-2025 | Otezla, Otezla, Enbrel |
| Sun Pharmaceutical Industries INC. | $396.76 | 2022-2025 | Winlevi, Ilumya, Blu-U |
| Merz North America, INC. | $185.09 | 2022-2024 | Xeomin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.96 | 2022-2025 | Spevigo, Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $126.47 | 2023-2024 | Siliq, Targretin, Cabtreo |
| Regeneron Pharmaceuticals, INC. | $75.17 | 2023-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 | |
| Janssen Scientific Affairs, LLC | $70.99 | 2024-2025 | Tremfya |
| Convatec INC. | $49.31 | 2025 | |
| Fresenius Kabi USA, LLC | $43.46 | 2023-2024 | Idacio |
| Lnhc, INC | $40.73 | 2025 | Zelsuvmi |
| Kerecis Limited | $33.83 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Springworks Therapeutics, INC. | $27.95 | 2025 | Gomekli |
| Biofrontera INC. | $21.23 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Revance Therapeutics, INC. | $15.13 | 2025 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Dasilva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.